secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268075
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials
--------------------------------------------------------------------------------

- Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.
- R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.
- Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.
- CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.
- New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/0001193125-25-268075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/clym-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer